GHK-Cu copper peptide: skin and hair research review

The GHK-Cu peptide is one of the fastest-growing peptides in search interest. It is not FDA-approved as a drug: topical GHK-Cu is sold as a cosmetic ingredient, and injectable GHK-Cu cannot currently be compounded in the US, with an FDA advisory committee review scheduled before the end of February 2027. The molecule itself is real: a naturally-occurring tripeptide-copper complex with demonstrated biological activity on skin, hair, and wound-healing biology. The hype, however, outruns the clinical evidence. Understanding the GHK copper peptide means separating the mechanism from the marketing.

What GHK-Cu actually is#

GHK-Cu is shorthand for glycyl-L-histidyl-L-lysine bound to copper(II). The tripeptide sequence (Gly-His-Lys) has high affinity for copper ions; when bound, the peptide-copper complex takes on the pale blue colour characteristic of copper(II) coordination compounds.

GHK was first isolated from human plasma in the 1970s. Levels in plasma decline with age, roughly 200 ng/mL at age 20, down to about 80 ng/mL by age 60. That age-related decline is part of the mechanistic argument for supplementation.

The copper ion matters. GHK without copper has some biological activity, but GHK-Cu (the copper-complexed form) has substantially more. Copper is a cofactor for lysyl oxidase (an enzyme critical for collagen cross-linking) and other enzymes involved in tissue remodelling.

The GHK-Cu mechanism#

GHK-Cu's documented activities in preclinical and cell-culture studies, summarised in a comprehensive review on PubMed, include:

• Collagen and elastin synthesis, GHK-Cu has been shown in fibroblast cultures to increase collagen and elastin production, which may support the skin-firmness use case
• Hair follicle stimulation, follicular dermal papilla cells respond to GHK-Cu with increased proliferation, an effect associated with hair-growth applications
• Wound healing, accelerated re-epithelialisation and reduced scarring in dermal wound models
• Antioxidant activity, GHK-Cu scavenges reactive oxygen species, providing some protection against oxidative damage
• Anti-inflammatory effects, modulation of inflammatory cytokine expression
• Gene expression modulation, broader effects on gene transcription related to tissue repair and maintenance

The mechanism is broader than most peptides. That breadth is both the appeal (many possible benefits) and a reason for scepticism (broad mechanism claims often fail to translate to robust clinical outcomes).

GHK-Cu peptide benefits, graded by evidence#

The most-cited GHK-Cu peptide benefits cluster around tissue repair, dermal collagen, and follicular biology. Research has shown the strongest signals in fibroblast and dermal-papilla cell culture, where GHK-Cu reliably increases collagen and elastin synthesis and modulates genes tied to wound resolution. Studies have shown smaller, less consistent effects in animal wound-healing models and very limited controlled human data outside the topical cosmetic literature. Preliminary evidence also points to antioxidant and anti-inflammatory activity at the cellular level, but the magnitude and translation to clinical endpoints in humans is not well established. Treating GHK-Cu peptide benefits as plausible mechanistic effects rather than confirmed clinical outcomes is the honest framing.

A separate category often confused with the research-use peptide is copper peptides for hair in topical cosmetic form. The research peptides covered in this guide are injectable formulations intended for research-use protocols. Topical cosmetic copper peptides marketed in shampoos, scalp serums, and follicle treatments operate as dermatological cosmetics rather than systemic therapeutics, and they sit in a different regulatory bucket. Cosmetic copper peptide hair products are out of scope for this guide; the injectable research-use protocols below address a different question entirely.

Topical vs injectable#

The strongest evidence for GHK-Cu is topical (applied to the skin):

• Decades of cosmetic and dermatological research
• Several small clinical studies on skin firmness, fine lines and wrinkles, plus a randomized, vehicle-controlled trial of a GHK-Cu gel in diabetic foot ulcers (Mulder et al., 1994)
• Included in skincare formulations globally
• Concentrations vary widely: a 2014 Cosmetic Ingredient Review assessment reported GHK in leave-on cosmetics at up to 0.001% (CIR, 2014), while products marketed as copper peptide serums often state higher strengths

Topical GHK-Cu is what sits in skincare products marketed in every major market, typically formulated as a copper peptide serum. The evidence for its cosmetic effects on skin texture and appearance is reasonable, and the copper peptide serum category is by some distance the most studied form of the molecule.

The injectable evidence base is thinner. Injected GHK-Cu has been studied in animals (wound healing in rats, mice and pigs), but no published human trial has tested injectable GHK-Cu. Injectable use is where research-use protocols and the fastest-growing search volume live, but it's also where the hype has the widest gap to close with the evidence.

Dosing#

For the research-use track, the GHK-Cu peptide injection dosage commonly used in protocols sits in the low-milligram range, with subcutaneous administration two to three times per week.

Injectable (research use):

• Dose: 1–2 mg per injection (Klarovel's curated band is also 1 mg to 2 mg, with 0.5 mg as a first-exposure start)
• Frequency: 2–3× weekly at the conservative end; some protocols dose daily
• Route: subcutaneous, can be injected near scalp for hair-focused protocols or abdominally for systemic effects
• Cycle length: 8–12 weeks per cycle

Topical (cosmetic):

• Formulations vary by product; follow the product label
• Applied to clean skin twice daily
• Avoid combining with topical retinoids on the same application (copper oxidises retinoids)

For the injectable path, a typical 50 mg GHK-Cu vial reconstituted with 2 mL BAC water gives 25 mg/mL. A 2 mg dose = 0.08 mL = 8 syringe units. The peptide calculator handles vial sizes.

Side effects#

Both topical and injectable GHK-Cu have benign side-effect profiles:

• Topical: occasional skin irritation, particularly in users with sensitive skin or copper sensitivity
• Injectable: mild injection-site irritation, transient blue-green discolouration at injection site (from the copper complex, cosmetic only), rare mild fatigue

The blue-green colour at the injection site is expected, it's the peptide-copper complex itself. It fades over hours as the peptide distributes.

Regulatory status#

Topical GHK-Cu is regulated as a cosmetic ingredient in most jurisdictions, no prescription required, standard cosmetic safety testing applies. Widely marketed in skincare products globally, including in Norway.

Injectable GHK-Cu is not approved as a medicine in the US, EU, or Norway. In the US, the FDA removed injectable GHK-Cu from Category 2 (substances that may present significant safety risks in compounding) and non-injectable GHK-Cu from Category 1 in April 2026, after the nominations were withdrawn, and scheduled both for its Pharmacy Compounding Advisory Committee before the end of February 2027 (FDA). No vote has been taken, so a 503A pharmacy cannot currently compound it; the regulatory status tracker follows each step. DMP has not authorised injectable GHK-Cu for any indication. GHK-Cu is not named on the WADA Prohibited List, though the S0 class covers non-approved substances in general.

Klarovel does not sell, source, or fulfil peptides. How you obtain GHK-Cu is outside the platform.

The honest framing#

The case for GHK-Cu is strongest where the evidence is strongest: topical cosmetic applications for skin texture, fine lines, and age-related collagen loss. That evidence base is legitimate.

The case for injectable GHK-Cu for systemic effects, whole-body collagen synthesis, metabolic effects, broad anti-aging, is less well supported. The mechanism is plausible and the preclinical data is real, but clinical trials at scale haven't been run. Claims of dramatic systemic benefits should be treated with the same scepticism applied to any research-use peptide without Phase 3 evidence.

The growth in search volume has run ahead of the clinical evidence for injection. Whether the search query is GHK-Cu, GHK Cu peptide, or GHK copper peptide, the underlying molecule is the same and the evidence base is the same. GHK-Cu is interesting pharmacology, it's not the first peptide where interesting pharmacology translated slowly to real-world outcomes.

Direct comparisons: TB-500 vs ghk-cu.

Practical framework#

Three questions for anyone considering GHK-Cu:

1. Topical or injectable? For skin-quality goals, topical has better evidence and lower regulatory friction. For research-use systemic applications or hair-focused protocols, injectable has the research framework.
2. What's the specific goal? Narrow, clear goals (wrinkle appearance, hair density support) are better matches for GHK-Cu than broad anti-aging intent. Broad goals are usually better addressed by multiple more-specific tools.
3. What's the stack fit? GHK-Cu pairs reasonably with BPC-157 for wound healing, with peptide-based hair protocols for follicular support, or with topical routines for cosmetic outcomes. It's rarely a standalone protocol.

For research-use protocol planning, Klarovel's questionnaire maps goals and contraindications to recommendations. The peptide calculator handles dose math. For tissue-repair context, see the BPC-157 guide and the broader peptides for healing overview.

GHK-Cu is a real molecule with real mechanism. The hype is partly earned and partly market-driven. Use it where the evidence is strongest (topical cosmetic) and keep expectations realistic for research-use injectable applications.